Loomis Sayles & Co. L P Grows Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Loomis Sayles & Co. L P grew its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 2.7% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 106,652 shares of the specialty pharmaceutical company’s stock after buying an additional 2,838 shares during the period. Loomis Sayles & Co. L P’s holdings in Jazz Pharmaceuticals were worth $11,882,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in JAZZ. Swedbank AB bought a new stake in Jazz Pharmaceuticals during the second quarter worth about $106,936,000. Rubric Capital Management LP bought a new stake in Jazz Pharmaceuticals in the 2nd quarter worth approximately $65,812,000. Pacer Advisors Inc. boosted its stake in Jazz Pharmaceuticals by 40.7% in the second quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock worth $194,346,000 after buying an additional 527,187 shares in the last quarter. Baupost Group LLC MA grew its position in Jazz Pharmaceuticals by 52.8% during the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock valued at $136,000,000 after acquiring an additional 440,552 shares during the last quarter. Finally, Millennium Management LLC raised its stake in shares of Jazz Pharmaceuticals by 1,808.4% during the second quarter. Millennium Management LLC now owns 450,872 shares of the specialty pharmaceutical company’s stock worth $48,122,000 after acquiring an additional 427,246 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Analyst Ratings Changes

JAZZ has been the subject of a number of research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. TD Cowen reduced their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Robert W. Baird boosted their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research note on Monday, November 18th. Cantor Fitzgerald restated an “overweight” rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Finally, StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Three analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $175.33.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $122.79 on Wednesday. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $134.17. The company’s 50-day moving average is $113.94 and its 200 day moving average is $110.81. The stock has a market capitalization of $7.42 billion, a P/E ratio of 17.29, a P/E/G ratio of 1.07 and a beta of 0.57.

Insiders Place Their Bets

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the transaction, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. This trade represents a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the sale, the executive vice president now directly owns 33,048 shares in the company, valued at $4,078,453.68. This trade represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 6,110 shares of company stock worth $720,160. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.